Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Circassi

- PMLiVE

NICE to reverse approval for Novartis’ asthma drug Xolair

Draft guidance doesn't recommend omalizumab for severe asthma

UK flag

MRC funds UK research using 22 AstraZeneca compounds

Provides £7m for projects covering Alzheimer’s, cancer, lung disease and rare conditions

- PMLiVE

GSK takes severe asthma antibody into phase III

Mepolizumab could help patients who cannot prevent attacks using current therapies

- PMLiVE

New CEO says AZ open to acquisitions to rebuild pipeline

Comments come as Q3 operating profit plummets 47 per cent

- PMLiVE

AstraZeneca signs IBS collaboration with Ironwood in China

Deal will also see Ironwood’s US sales force promote Nexium for gastroesophageal reflux disease

AZ’s MedImmune partners with global cancer institutes

Will research combinations of immunotherapies

- PMLiVE

AZ pays $273m for Ardelyx renal disease drug

Phase II candidate could tackle fluid overload in kidney and heart disorders

- PMLiVE

AZ share buyback suspension prompts M&A speculation

Analysts query new CEO Pascal Soriot’s intention to preserve cash reserves

- PMLiVE

AZ launches science blog LabTalk

Hopes new blog will build relationships with potential collaborators

- PMLiVE

AstraZeneca drops Palatin’s obesity drug after trial subject suffers allergic reaction

But collaboration with the US biotech remains in place

- PMLiVE

COPD-asthma cases set to grow in Europe as people live longer

Study also highlights the respiratory burden the elderly will face

Problems at home can prevent children taking asthma drugs

Busy parents and financial problems could lead to poorer medicine adherence

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links